EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study
NCT ID: NCT00216255
Last Updated: 2012-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
120 participants
INTERVENTIONAL
2005-04-30
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pagoclone
.15mg, .30mg, .60mg
Pagoclone
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pagoclone
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* English-speaking, with 8th grade education, able to understand and cooperate with study requirements without assistance
* Not pregnant or breastfeeding
* Able to consent
Exclusion Criteria
* No use of psychotropic medication or other medication for stuttering within 4 weeks prior to screening
* No use of non-medicinal stuttering treatments for 5 months prior to the study
* No use of illicit drugs or opiates of any kind
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Endo Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pivotal Research Centers
Peoria, Arizona, United States
University of California, Irvine Medical School
Orange, California, United States
Pharmacology Research Institute
Riverside, California, United States
Pacific Clinical Research Medical Group
Upland, California, United States
University of South Florida College of Medicine
Tampa, Florida, United States
Atlanta Institute of Medicine & Research-Atlanta Clinic
Atlanta, Georgia, United States
Davis Clinic PC
Indianapolis, Indiana, United States
Vince and Associates Clinical Research
Overland Park, Kansas, United States
Pivotal Research Centers
Royal Oak, Michigan, United States
Social Psychiatry Research Institute
Brooklyn, New York, United States
Social Psychiatry Research Institute
New York, New York, United States
Midwest Clinical Research Center
Dayton, Ohio, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
FutureSearch Trials
Austin, Texas, United States
University of Texas, Health Science Center
San Antonio, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IP456-039
Identifier Type: -
Identifier Source: org_study_id